Verrica Pharmaceuticals Announces Positive Preliminary Topline Results from Part 2 of Phase 2 Clinical Study of VP-315, an Investigational Oncolytic Peptide-Based Immunotherapy for the Treatment of Pa

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/9/2026

1. TTAN
2. BRZE
3. CHYM
4. USO
5. QCOM
6. IRT
7. ASO
8. UNFI
9. SPY
10. EVMN

Go back to Verrica Pharmaceuticals Announces Positive Preliminary Topline Results from Part 2 of Phase 2 Clinical Study of VP-315, an Investigational Oncolytic Peptide-Based Immunotherapy for the Treatment of Pa
(NASDAQ: VRCA) Delayed: 5.40 +0.14 (2.66%)
Previous Close $5.26    52 Week High $ 
Open $5.25    52 Week Low $ 
Day High $5.40    P/E N/A 
Day Low $5.25    EPS $ 
Volume 7,523